Treatment of the Nasolabial Fold Using a Hyaluronic Acid-Based Filler with eXcellent Three-Dimensional Reticulation (XTRTM) Technology: A Retrospective Study
Abdulrahman Abdulbaky,Vincent Wong
DOI: https://doi.org/10.2147/ccid.s427736
2024-03-09
Clinical Cosmetic and Investigational Dermatology
Abstract:Abdulrahman Hassan Imam Abdulbaky, Vincent Wong TriVin Aesthetics, London, UK Correspondence: Vincent Wong, TriVin Aesthetics, 10 Harley Street, London, W1G 9PF, UK, Tel +44 207 299 0380, Fax +44 207 467 8312, Email Purpose: The physicochemical characteristics of hyaluronic acid (HA) fillers can affect the outcome of minimally invasive aesthetic treatments. The effect of a novel HA-based filler manufactured with a novel 3D structure (XTR TM technology) was assessed in the nasolabial fold. Patients and Methods: We performed a retrospective study of patients who underwent treatment of the nasolabial fold with a novel HA filler in our clinic. Treatment outcome was assessed at 3 and 6 months with wrinkle score, GAIS, and VAS. Results: Eighteen patients were injected with the novel HA filler in the nasolabial fold. At six months, mean wrinkle scores were improved on both sides compared to baseline. GAIS and VAS were high at three and six months. Conclusion: The HA-based filler manufactured with XTR TM technology is safe and effective in treating the nasolabial fold. Good aesthetic results were seen for up to 6 months. Patient satisfaction was high during the entire follow-up. Keywords: filler injection, face rejuvenation, monophasic, crosslinking technology Hyaluronic acid (HA)-based fillers are a growing trend for minimally invasive rejuvenation. The physical properties of these hydrogels vary according to the chosen manufacturing approach allowing for a wider range of clinical applications. Indeed, commercially available HA-base fillers present distinct properties – HA concentration, degree of crosslinking, cohesivity levels, and rheology properties – depending on their formulation. 1 In addition, some fillers also incorporate lidocaine with a dual effect: to reduce pain due to its anesthetic properties and to diminish bruising and swelling due to antihistamine action. 2 Recently, the development of a new technology – eXcellent Three-dimensional Reticulation – has allowed to formulate a range of HA-based fillers with a particularly stable 3D structure. 1 In brief, the innovative manufacturing process can be broken down into 3 phases: pretreatment, crosslinking, and purification. The pretreatment phase is a thermal-controlled fracturing step that forms skin-compatible HA chains of medium and high molecular weight. This mixture of HA chains is bound into a stable matrix using a crosslinking agent during the crosslinking phase. This step is optimized, meaning there is minimal presence of free HA chains in the final product. The most common molecule used during crosslinking is BDDE (1,4-butanediol diglycidyl ether). The last step is the purification of the product, that is, the elimination of unreacted BDDE and byproducts. Each batch of XTR TM fillers is set to have minimal levels of unreacted BDDE (<2 ppm, as per the recommendation of the US Food and Drug Administration). The entire manufacturing process is developed to achieve optimal levels of size, crosslinking, and purity of HA fillers, critical to enhancing its biological effects on the skin, namely filling properties, and durability. In addition, the enhanced crosslinking step is particularly important to achieve stable viscoelastic properties that reduce extrusion during injection. The technology allows the manufacturing of high-quality gels with varying concentrations of HA and different G' to better adapt to the patients' needs. 1 Fillers with higher HA concentration and storage modulus (G') – such as Definisse core + lidocaine – are classified as volumizers, while Definisse restore + lidocaine is more suited for tissue projection and correction of facial defects with minimal amount of product. 1,3,4 Here, we describe our experience with Definisse restore + lidocaine on the correction of the nasolabial fold by performing a retrospective analysis of patients who came to our clinic requesting this minimally invasive treatment. This is a single-center, observational, retrospective study conducted on patients who underwent treatment of the nasolabial fold with Definisse restore plus lidocaine (Relife srl, Italy) between 1st November 2021 and 28th February 2022. Follow-up was done at two weeks, three, and six months. Patient eligibility criteria were the following: being female, aged between 25 and 65 years old, not pregnant/breastfeeding, without systemic illnesses, body dysphoria, or mental health concerns, with realistic expectations, and without fillers in the area for at least 18 months prior to enrollment. Injections were performed with Definisse restore plus lidocaine filler (Relife S.r.l., Italy): 0.2mL slow bolus to deep pyriform space (supraperiosteal), and 0.3mL to nasolabial fold -Abstract Truncated-
dermatology